IRON Disc Medicine, Inc.
FY2025 10-K
Disc Medicine, Inc. (IRON) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: clinical-stage biopharma developing novel treatments targeting red blood cell biology, focusing on heme biosynthesis and iron homeostasis pathways
- • New emphasis: submission of NDA for bitopertin in erythropoietic porphyrias (EPP and XLP) with FDA accelerated approval pursuit, ongoing Phase 3 APOLLO trial initiated May 2025
Management Discussion & Analysis
- • No revenue generated; net loss $212.2M in 2025 vs $109.4M in 2024, loss doubled YoY
- • Operating expenses up $106.3M YoY: R&D $170.6M vs $96.7M, SG&A $65.4M vs $33.0M
Risk Factors
- • Regulatory risk: Dependency on FDA approval timing and conditions for product candidates impacts commercialization and cost structure
- • Macroeconomic threat: Cash runway extends only to 2029 with $791.2M liquidity; accelerated spending could exhaust funds earlier
Financial SummaryXBRL
Net Income
-$212M
ROE
-28.7%
Total Assets
$807M
EPS (Diluted)
$-6.01
Operating Cash Flow
-$180M
Source: XBRL data from Disc Medicine, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Disc Medicine, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.